France cardiac biomarker market is estimated to grow significantly at a CAGR of around 6.6% during the forecast period. The rising incidences of CVD result in the diagnosis rate propelling the cardiac biomarker market. According to the Global Burden of Disease Database, in 2010, France accounted for about 269,093 new male cases and 277,334 new female cases of CVD. These cases increased to the value of 286,394 in males and 296,370 in females in 2015. This high number of CVD cases shows the market potential for a diagnostic biomarker for cardiology in the region due to application in the diagnosis of CVD. The presence of some biomarker companies such as Biomerieux, Cisbio Bioassays, and others. These companies are prevailing the diagnostic biomarker market by providing new and advance biomarker tests, for instance, Biomerieux provides VIDAS highly sensitive Troponin I test that is used in the diagnosis of the Acute Coronary Syndromes (ACS).
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/france-cardiac-biomarker-market
The market is segmented on the basis of type, application, and location of testing. Based on type, the market is segregated into Creatine kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others. The troponin is anticipated to be the fastest growing and has a considerable market share in the France cardiac biomarker market due to easy and high sensitivity that results in the high adoption of the test. Based on Application, the market is segmented into myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. On the basis of the location of testing, the market is classified into laboratory testing and point of care testing.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/france-cardiac-biomarker-market
The companies which are contributing to the growth of the France cardiac biomarker market include Abbott Laboratories, BioMérieux S.A., Cisbio Bioassays SAS, Danaher Corp., F. Hoffmann-La Roche AG, HyTest Ltd, Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Market Segmentation
France Cardiac Biomarker Market by Type
- Creatine kinase (CK-MB)
- Troponins(T,I)
- Myoglobin
- Natriuretic peptides (BNP & NT-PROBNP)
- Ischemia modified albumin
- Others
France Cardiac Biomarker Market by Application
- Myocardial infraction
- Congestive heart failure
- Acute coronary syndrome
- Atherosclerosis
- Others
France Cardiac Biomarker Market by Location of Testing
- Laboratory testing
- Point of care testing
Company Profiles
- Abbott Laboratories
- BioMérieux S.A.
- Cisbio Bioassays SAS
- Danaher Corp.
- Hoffmann-La Roche AG
- HyTest Ltd
- Merck KGaA
- Randox Laboratories Ltd.
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
